Načítá se...
PF-06438179/GP1111: An Infliximab Biosimilar
PF-06438179/GP1111 (Zessly(®); Ixifi(®)) [hereafter referred to as GP1111] is a biosimilar of the reference monoclonal anti-TNF-α antibody infliximab, and is approved in the EU and USA for the same indications as the reference drug, including rheumatoid arthritis (RA), Crohn’s disease, ulcerative co...
Uloženo v:
| Vydáno v: | BioDrugs |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6290860/ https://ncbi.nlm.nih.gov/pubmed/30284704 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-018-0310-5 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|